MedMira Strengthens and Expands Board
Halifax, Nova Scotia, 14 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the...
MedMira Strengthens and Expands Board
MedMira Receives Patent for its Unique Quantitative Diagnostic System
Update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
VYRAâ„¢ Product Line Update
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
Corporate update
MedMira Provides a Pre-Annual General Meeting Update
MedMira Announces VYRAâ„¢ CoV2Flu and Additional Regulatory Opportunities
MedMira strengthen its Board with New Appointment
MedMira announces significant debt reduction and additional growth capital
Performance Update on World Health Organisation SARS-CoV2 Serology Standards
Product and Regulatory Update on MedMira’s COVID-19 Product Family
Progress Update on MedMira’s COVID-19 Product Family
MedMira Announces Product Update
MedMira reports additional independent performance evaluation results of REVEALCOVID-19â„¢
MedMira Announces Update on Development of Point-of-Care Antibody Test